The performance of companies tied to Viagra's legacy presents a complex investment landscape. While the initial boom generated substantial returns , generic alternatives have significantly eroded revenue. Investing in associated pharmaceutical companies now requires a discerning assessment of intellectual property rights , evolving healthcare chang